Mr. Stephen Van Deventer reports

PREVECEUTICAL ANNOUNCES DATE FOR ANNUAL GENERAL AND SPECIAL MEETING

Preveceutical Medical Inc. has scheduled its annual general and special meeting for Aug. 15, 2025, at which the shareholders of the company will be asked to approve:

1. The election of Stephen Van Deventer, Makarand Jawadekar, Linnea Olofsson, Kathleen Rokita and C. Evan Ballantyne as directors of the company;
2. The ratification of the appointment of Davidson & Company LLP, chartered professional accountants, as the auditor of Preveceutical for the financial year ending Dec. 31, 2024, and 2025;
3. A plan of arrangement under the provisions of Division 5 of Part 9 of the Business Corporations Act (British Columbia), pursuant to which the company will distribute up to 12 million common shares of BioGene Therapeutics Inc. to the Preveceutical shareholders; and
4. The adoption of the Preveceutical's omnibus equity incentive plan.

Once the arrangement and distribution is complete, the Preveceutical shareholders will own shares in two companies: BioGene, which will focus on the development of the dual gene therapy program, and Preveceutical, which will continue to focus on developing innovative options for preventive and curative therapies utilizing organic and nature identical products.

Preveceutical believes that the arrangement and distribution are in the best interests of Preveceutical and the Preveceutical shareholders for numerous reasons, including that separating Preveceutical and BioGene will expand both Preveceutical's and BioGene's potential shareholder base and access to capital for research, development and clinical trials by allowing investors who want specific ownership in the particular business of BioGene the opportunity to invest directly in BioGene rather than through Preveceutical.

About Preveceutical Medical Inc.

Preveceutical is a health science company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. Preveceutical aims to be a leader in preventive health sciences, and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel program; nature identical peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).